Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）

This study (neoSCORE II) is testing whether adding sintilimab (an immunotherapy drug) to standard chemotherapy before surgery improves outcomes for people with resectable squamous cell non-small cell lung cancer (NSCLC) — a specific type of lung cancer — allowing more people to successfully undergo surgery after shrinking the tumor first. **You may be eligible if:** - You are between 18 and 75 years old - You have squamous cell NSCLC confirmed by biopsy - Your cancer has not been treated before and is classified as resectable Stage IIA–IIIB - Your general health is good (ECOG 0–1) - Your life expectancy is more than 6 months - Your blood counts, liver, kidney, and thyroid function are within acceptable ranges **You may NOT be eligible if:** - You have non-squamous NSCLC (e.g., adenocarcinoma) - You have previously received any treatment for this cancer - You have severe organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.